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ABSTRACT
INTRODUCTION: Drug-drug interactions (DDIs) are common but avoidable causes for adverse drug re-
actions. 
AIM: The present pilot study aimed to assess the prevalence of potential DDIs (pDDIs) among patients with 
psychiatric disorders by evaluation of patients’ hospital records and their discharge medication lists. 
MATERIALS AND METHODS: A retrospective review of medication information was conducted for 47 
male patients consecutively admitted for a period of one month to the acute unit of a university-based psy-
chiatric clinic. Potential DDIs were checked with Medscape drug interaction checker and standard referenc-
es on drug interactions, and were classified as major, moderate, or minor according to their severity. The 
statistical analysis included: Chi-square test, Student’s t-test, and correlation analysis. 
RESULTS: For the duration of the hospitalization a total of 121 interacting drug pairs were detected, po-
tentially capable of inducing DDIs (2.57 per patient). Out of all the patients 44 (94%) were exposed to at least 
one pDDI and 7 (15%) to at least one serious pDDI. The most common potential risk was the additive seda-
tive effect, involving 58 drug pairs with an average rate of 1.23 per patient. QTc prolonging drug combina-
tions were found in 11 (23%) patients, drug combinations with potential risk of hematologic toxicity in 10 
(21%) patients and such with potential risk of hepatic/metabolic toxicity in 9 (19%). CYP-mediated pDDIs 
were identified in 8 (17%) patients. At hospital discharge fewer pDDIs per patient (1.13) were detected.
CONCLUSION: A high prevalence of pDDIs among the psychiatric inpatients was recorded. Caution is 
warranted to limit the exposure of the patients to pDDIs.
Keywords: potential drug-drug interactions, psychiatric patients, discharge medications
INTRODUCTION
Drug-drug interactions (DDIs) are among the 
most common causes for adverse drug reactions 
(ADRs). They constitute about 26% of the ADRs 
leading to hospital admissions (1). At the same time, 
they are a preventable medication-related risk to pa-
tients (2). Good knowledge of the mechanisms and 
the predisposing factors leading to DDIs is a prereq-
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tients successively hospitalized in November 2016 in 
an intensive psychiatric unit of the University Hospi-
tal in Varna. The medical records of the patients were 
reviewed and the following data were collected: pa-
tient’s age, length of hospital stay, psychiatric diagno-
sis, drugs prescribed during hospital stay and at dis-
charge. To identify pDDIs, the free Drug Interaction 
Checker platform of Medscape and standard refer-
ences on drug interactions were used.
DDIs were classified as major (serious, contra-
indicated), moderate or minor, according to their se-
verity and as pharmacokinetic or pharmacodynamic 
according to their mechanism. The pDDIs were ana-
lyzed in respect to the exposure of the patients to cer-
tain potential risks or presumed organ toxicity. 
Drugs known to have a low therapeutic index, 
to exhibit potentially severe side effects and to inhib-
it or induce drug-metabolizing enzymes, mainly cy-
tochrome P450 (CYP) isoforms were given particu-
lar attention.
Data analyses: Chi-square test was used to com-
pare the exposure to pDDIs during hospital stay and 
at discharge from hospital, with p<0.05 being con-
sidered as the level of significance. Student’s t-test for 
comparison of two means and correlation analysis to 
identify the strength of relationships between vari-
ables were performed. 
The study has been approved by the inter-
nal Ethical Committee of the Medical University of 
Varna.
RESULTS 
The patient sample included 47 men aged 19-
68 years (mean age 43.7, SD: ±12.5). The most com-
mon diagnosis was paranoid schizophrenia (22 pa-
tients), followed by bipolar affective disorder (11 pa-
tients). Seven patients were treated for psychic and 
behavioral disorders caused by alcohol or substance 
use with or without abstinence, 4 for a depressive ep-
isode, and 1 for dementia. One patient was diagnosed 
with moderate mental retardation and another with 
emotional instability with alcohol abuse. 
Hospital length of stay ranged from 6 to 46 
days, with a mean of 20 days.  
A total of 175 of drugs were prescribed to the 
patients during the observed period.  Out of these: 
49 were antipsychotics, 42 – anxiolytics, 35 – anti-
uisite to avoiding drug combinations associated with 
potential toxicity or inefficacy.
Based on their mechanisms, two major types 
of DDIs are distinguished: pharmacokinetic and 
pharmacodynamic. In general, the pharmacokinet-
ic DDIs are considered to be more common and clin-
ically relevant. These interactions occur when one 
drug alters the concentration of another drug with 
clinical consequences. The pharmacodynamic DDIs 
occur between drugs with additive or opposing ef-
fects and can result in significant toxicity or reduced 
effects. The brain is the organ most commonly com-
promised by pharmacodynamic interactions (3). 
DDIs are not equally relevant for the clinical 
practice. According to the clinical severity of the po-
tential result they are usually classified into three cat-
egories: serious or severe (drug combinations should 
generally be avoided whenever possible, as they can 
result in potentially serious toxicity or lack of effica-
cy), moderate (requiring an alteration in drug dosage 
or increased monitoring), and minor or mild (which 
have limited clinical impact and require no change 
of therapy). 
Old age, polypharmacy, long hospital stays, 
gender, and comorbid conditions have been reported 
as common risk factors for DDIs (4).
Few studies have addressed the issue of DDIs 
in psychiatric wards (5-8). On the other hand, anti-
psychotics, antidepressants, and mood stabilizers are 
among the bulleted drugs listed in the drug interac-
tions appendix of the British National Formulary, 
signifying ‘interactions that are potentially hazard-
ous and where combined administration of the drugs 
involved should be avoided’ (9).
AIM
The aim of the present study, designed as a pi-
lot clinical investigation, was to evaluate retrospec-
tively the prevalence of potential DDIs (pDDIs) in 
male patients with psychiatric disorders both during 
their hospital stay and at discharge from a university-
based intensive psychiatric unit, and to make a com-
parison of the exposure to pDDIs of the patients as 
inpatients and outpatients.
MATERIALS AND METHODS 
This retrospective cross-sectional clinical in-
vestigation involved a sample of 47 adult male pa-
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epileptic drugs, 16 – antidepressants, 2 – anticholin-
ergic drugs, 2 – cognitive enhancers and 1 – lithium. 
Administered occasionally were 28 non-psychotro-
pic drugs intended to treat comorbidities.
Hospitalization period: Diazepam was the most 
frequently prescribed drug (35 patients), followed by 
sodium valproate (24 patients), and olanzapine (14 
patients). These drugs were also most commonly in-
volved in pDDIs.
A total of 121 pDDIs (2.57 per patient) were de-
tected for the period of the hospital stay, and most of 
them – 103 (2.19 per patient) – were of moderate se-
verity, followed by 9 (0.19 per patient) of serious se-
verity and 9 of minor severity. Out of all patients 44 
(94 %) were exposed to at least one pDDI and 7 (15%) 
of the patients received at least one drug pair with the 
potential to cause a serious adverse event. 
All pDDIs, except those associated with chang-
es in cytochrome P450 activity – 8 (17%), were phar-
macodynamic interactions. Most relevant to clinical 
practice were the synergistic pDDIs resulting in in-
creased sedative effect, QTc interval prolongation, 
extrapyramidal side effects, and serotonin syndrome. 
Two of the pDDIs with pharmacokinetic mechanism 
were considered clinically relevant i.e. metoprolol 
overdose and reduced efficacy of diazepam.
Out of all pDDIs 58 (48%) resulted in potential-
ly synergistic sedative effect of both drugs, represent-
ed by drug pairs prescribed to 42 patients (1.38 per 
patient). Diazepam was involved in 41 of these pD-
DIs that affected 35 patients. 
Eleven drug pairs prescribed to the patients 
while hospitalized were associated with pDDIs, 
which could lead to QTc interval prolongation. Olan-
zapine, escitalopram, chlorpromazine, and clozapine 
were mainly involved in these drug combinations.
Drug pairs synergistic in causing blood dys-
crasias were prescribed to 10 patients, with the drug 
combination being almost exclusively olanzapine and 
sodium valproate. The same drug pair is also associ-
ated with pDDIs that could result in increased liv-
er enzymes and weight gain. Five drug pairs showed 
synergism leading to extrapyramidal side effects and 
two - to serotonin syndrome.
Pharmacokinetic pDDIs caused by changes in 
cytochrome P450 activity were detected in eight pre-
scriptions, involving mainly carbamazepine and ox-
carbazepine, as well as fluoxetine, paroxetine, dulox-
etine, haloperidol, and chlorpromazine.
Hospital discharge lists: 128 drugs were pre-
scribed, among which 53 drug pairs were identified 
as leading to pDDIs (1.13 per patient). Most of them 
– 43 (0.91 per patient) – were of moderate severity, 5 
(0.11 per patient) were of serious severity, and 5 were 
of minor severity. Out of the detected pDDIs in the 
discharge medication lists, only 6% were CYP-based.
Out of all patients at discharge, 24 (51%) were 
exposed to at least one pDDI, 23 (49%) of these to at 
least one moderate or serious pDDI. The ADRs that 
could result from the pDDIs at discharge were hema-
tological ADRs (10 patients), QTc interval prolonga-
tion (9 patients) and sedation (6 patients).
Characteristics Inpatients Outpatients p
Patients with at least one pDDI - overall 44/ 93.6% 24/ 51.1% < 0.001
Patients with at least one serious pDDI 7/ 15.0% 3/ 6.4% > 0.05
Patients with at least one  moderate pDDI 44/ 93.6% 20/ 42.6% < 0.05
N of pDDIs - overall/per patient 2.57 1.13 < 0.01
N of serious pDDIs/per patient 0.19 0.11 > 0.05
N of moderate pDDIs/per patient 2.19 0.91 < 0.01
N of minor pDDIs/per patient 0.19 0.11 > 0.05
N-number, pDDI - potential Drug-Drug Interactions
Tabl. 1. Distribution of pDDIs based on their severity
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The drugs involved most frequently in the pD-
DIs at discharge were olanzapine (16 pairs), valproate 
(10 pairs), aripiprazole and clozapine (7 pairs each), 
trazodone (6 pairs), escitalopram (4 pairs), etc.
The number of prescribed medications was the 
only factor significantly associated with the number 
of the detected pDDIs, both during the hospital stay 
(Pearson r=0.667; p < 0.001) and at discharge (Pear-
son r=0.727; p < 0.001). There was no significant as-
sociation between the age of the patients and the 
length of the hospital stay with the number of the de-
tected pDDIs in our study.
Psychiatric diagnosis tended to have an impact 
on the number of the detected pDDIs: for the hos-
pitalization period the patients with bipolar disor-
der (n=11) had non-significantly higher number of 
pDDIs (3.18 per patient), compared to patients with 
paranoid schizophrenia (2.13 per patient). At dis-
charge, however, the difference became significant 
(p=0.0007).
DISCUSSION
This was a pilot retrospective study aiming to 
assess the frequency and nature of pDDIs associated 
with pharmacotherapy of psychiatric disorders. Pa-
tients with such disorders are at particular risk for 
DDIs because of the practice of symptom-based pre-
scribing, longer hospital stays and multiple prescrib-
ers, and medical, including psychiatric, comorbidity. 
DDIs contribute significantly to hospital admissions, 
treatment failures, avoidable medical complications, 
and subsequent healthcare costs (10, 11).
Our results show a high frequency of pDDIs 
among hospitalized psychiatric patients. Results very 
close to our data (96% pDDIs) were reported by Va-
sudev and Harrison (2008) in a study among hospi-
talized elderly psychiatric patients in Great Britain 
(5). However, Ismail et al. (2012) and Ocana-Zuri-
ta et al. (2016) reported a lower frequency of pDDIs 
among hospitalized psychiatric patients in Pakistan 
and Mexico, respectively (8,12).
The rate of the pDDIs for the patients at dis-
charge in our study (51%) was significantly lower 
than that found for the period of the hospitalization. 
An epidemiological study on schizophrenic outpa-
tients, based on prescriptions in a large US state’s 
Medicaid claims database, revealed a rate of pDDIs 
of 23%, while in a mixed Turkish population of in-
patients and outpatients with schizophrenia, a rate as 
high as 71% was reported (13,14). 
The variation in the reported data may be at-
tributed to a number of factors. An essential one is 
the different sources used in the studies to check the 
pDDIs. Vasudev and Harrison (2008) stressed this is-
sue, using the results of their study to question the 
concordance of two well-referenced databases they 
had used (5). We have encountered similar problems 
with two other databases, choosing one of them in 
addition to other references. 
Other factors influencing the rate of the pDDIs 
are the age of the study population, the psychiatric 
diagnoses of the patients, the mechanism of the eval-
uated pDDIs, and the study designs. The higher prev-
alence of pDDIs for the psychiatric inpatients in our 
study may be partly due to the entirely male sample, 
the acute setting of the patient unit, and the mode of 
prescribing associated with psychiatric emergencies. 
In their survey, Davies et al. (2004) focused on CYP-
based pDDIs in two subgroups of patients – adults 
and elderly – and demonstrated a higher rate of pD-
DIs related to CYP3A4 for the functional elderly pa-
tients (6). 
Paranoid schizophrenia was the psychiatric di-
agnosis in 47% of the patients in our study popula-
tion. In part this could give an explanation for the 
different results of other studies focusing on schizo-
phrenia only (13,14). Bipolar affective disorder was 
the diagnosis in 23% of the patients and these pre-
scriptions actually accounted for a higher prevalence 
of pDDIs in our patient sample. 
Mechanisms of the evaluated interactions are 
relevant to the reported results.  The studies of Da-
vies et al. (2004) and Guo et al. (2012) were focused 
exclusively on CYP-based pDDIs (6, 13), while in our 
research we were interested in both types of pDDIs: 
pharmacokinetic and pharmacodynamic. Out of all 
detected pDDIs for the period of the hospital stay in 
our study only 17% were CYP-based and for the dis-
charge medications the rate was 6%. The pharma-
cokinetic pDDIs involved both inducers and inhib-
itors of cytochrome P450 enzymes as carbamaze-
pine, oxcarbazepine, paroxetine, fluoxetine, dulox-
etine, haloperidol, and silymarin, prescribed in drug 
pairs with diazepam, valproic acid, aripiprazole, and 
metoprolol. The main CYP isoform involved was 
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CYP 2D6. Similar findings were reported by Davies 
et al. (2004) (6).
We determined the frequency and nature of 
the pDDIs for the same patient population in differ-
ent clinical settings. The significant difference of the 
rate of the pDDIs during the hospital stay (2.57 per 
patient) and at discharge (1.13 per patient) (p<0.01) 
could be explained by the severity of the psychiatric 
conditions under treatment. 
Analysis of the pharmacodynamic pDDIs 
showed exposure to certain potential risks regardless 
of the clinical setting in which they were identified 
such as additive sedative effects of the administered 
drugs, possible QTc prolongation, potential risk of 
hematologic toxicity and/or hepatic/metabolic toxic-
ity. While the additive sedative effect was significant-
ly more associated with the hospital stay than the dis-
charge period (p<0.01), the risk of QTc prolongation 
was not significantly associated with the clinical set-
ting. A prolonged QTc often arouses concern in clini-
cal practice, as it can be followed by the life-threaten-
ing polymorphic ventricular tachyarrhythmia called 
torsade de pointes (TdP) (15). Psychotropic drugs 
are commonly associated with such kind of pDDIs, 
which fall under the category of moderate-to-serious 
interactions depending on the potential of the par-
ticular drug to prolong the QTc interval. The main 




lithium carbonate, olanzapine-mirtazapine, fluox-
etine-olanzapine. It should be noted, however, that 
drug-induced QTc prolongation and/or TdP usually 
occur in patients with underlying risk i.e. age over 
65 years, pre-existing cardiovascular disease, brady-
cardia, female sex, hypokalemia, hypomagnesemia, 
high therapeutic or toxic serum concentration of the 
prescribed drug, often in the setting of polypharma-
cy or the simultaneous administration of other drugs 
that delay repolarization or interfere with drug me-
tabolism (15,16). Thus, it is strongly recommended 
that the concomitant use of medications known to 
prolong the QTc interval should be avoided in vul-
nerable patients (15-17). Aripiprazole appears to be 
the safest alternative among the atypical antipsy-
chotics in terms of cardiotoxicity and should be con-
sidered in cases of increased risk of rhythm disorders 
(17).
Psychotropic drugs can cause a variety of blood 
dyscrasias, although it is still difficult to estimate the 
true prevalence of such risks (18). The pDDIs associ-
ated mainly with a risk of thrombocytopenia in our 
study were linked especially to the drug pair of olan-
zapine/valproic acid. An early review on hematolog-
ical side effects of psychotropic drugs mentions val-
proic acid as causing anemia, neutropenia, pure red 
cell aplasia and thrombocytopenia, and olanzapine 
as inducing leukocytosis and thrombocytopenia (19). 
Furthermore, recent evidence associates olanzapine 
with leukopenia, even recommending that the guide-
lines for using and monitoring olanzapine be recon-
sidered (20-22).
The same drug combination could also expose 
the patients to additive liver damage. Valproic acid 
may cause serious or even life-threatening damage 
to the liver that is most likely to occur in the first 6 
months after starting treatment (23,24). Olanzapine, 
in its turn, has also been reported to cause liver in-
juries of variable severity through different mecha-
nisms (25,26). Nonalcoholic fatty liver disease can 
also be associated with atypical antipsychotics via 
the metabolic abnormalities, which they can induce 
(27). Caution is warranted after starting a psychotro-
pic agent in a patient with hepatic impairment, espe-
cially in combination with valproic acid. Use of psy-
chotropic drugs with minimal liver metabolism and 
monitoring the levels of aminotransferases is con-
sidered appropriate in such occasions (28,29). Other 
ADRs that olanzapine and valproate share are weight 
gain, somnolence, tremor, dry mouth, and speech 
disorders (20).
CONCLUSION
A high rate of pDDIs was detected in our pa-
tient sample for the period of the hospital stay and 
less so at discharge. Although it has been found that 
pDDIs far outnumber those which lead to clinically 
significant effects, analysis has shown that the real 
size of the adversely affected patients is neverthe-
less large enough (30). It is evident that pDDIs lead 
to ADRs only in the presence of a variety of predis-
posing risk factors. Given the high incidence of pD-
DIs, their clinical relevance should not be underes-
timated. Together with the careful clinical, physio-
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logical and biochemical monitoring of the patients, it 
is essential to consider the pharmacological features 
of the administered drugs and select those with the 
least propensity to interact.
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